Compare NWN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWN | AGIO |
|---|---|---|
| Founded | 1859 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2018 | 2013 |
| Metric | NWN | AGIO |
|---|---|---|
| Price | $53.35 | $27.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $54.33 | $39.88 |
| AVG Volume (30 Days) | 182.4K | ★ 1.0M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 36.45 | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,289,363,000.00 | $43,011,000.00 |
| Revenue This Year | $11.37 | $76.75 |
| Revenue Next Year | $4.46 | $170.73 |
| P/E Ratio | $19.52 | ★ N/A |
| Revenue Growth | ★ 11.83 | N/A |
| 52 Week Low | $39.29 | $22.24 |
| 52 Week High | $55.99 | $46.00 |
| Indicator | NWN | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 34.32 |
| Support Level | $45.72 | $26.64 |
| Resistance Level | $53.61 | $29.69 |
| Average True Range (ATR) | 1.01 | 1.52 |
| MACD | -0.23 | -0.41 |
| Stochastic Oscillator | 21.19 | 9.27 |
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.